1. Home
  2. EHC vs QGEN Comparison

EHC vs QGEN Comparison

Compare EHC & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Encompass Health Corporation

EHC

Encompass Health Corporation

HOLD

Current Price

$106.49

Market Cap

10.7B

Sector

Health Care

ML Signal

HOLD

Logo Qiagen N.V.

QGEN

Qiagen N.V.

HOLD

Current Price

$41.05

Market Cap

10.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EHC
QGEN
Founded
1983
1986
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7B
10.2B
IPO Year
1994
1998

Fundamental Metrics

Financial Performance
Metric
EHC
QGEN
Price
$106.49
$41.05
Analyst Decision
Strong Buy
Buy
Analyst Count
7
8
Target Price
$143.29
$50.26
AVG Volume (30 Days)
866.9K
1.3M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
0.71%
5.84%
EPS Growth
24.22
N/A
EPS
5.54
N/A
Revenue
N/A
N/A
Revenue This Year
$9.33
$8.18
Revenue Next Year
$8.14
$5.71
P/E Ratio
$19.20
$24.01
Revenue Growth
N/A
N/A
52 Week Low
$92.77
$38.80
52 Week High
$127.99
$57.82

Technical Indicators

Market Signals
Indicator
EHC
QGEN
Relative Strength Index (RSI) 59.58 44.85
Support Level $105.88 $38.80
Resistance Level $109.21 $48.53
Average True Range (ATR) 2.44 0.79
MACD 0.55 0.34
Stochastic Oscillator 81.03 53.32

Price Performance

Historical Comparison
EHC
QGEN

About EHC Encompass Health Corporation

Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, which is the company's sole segment. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. The company's inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.

About QGEN Qiagen N.V.

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).

Share on Social Networks: